Clinical trial
Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain
Name
20171217
Description
A randomized and blind clinical consistency study for three commercial batches of Inactivated Poliomyelitis Vaccine Made From Sabin Strain (sIPV) for immunogenicity and safety evaluation.
Trial arms
Trial start
2018-04-15
Estimated PCD
2019-02-25
Trial end
2019-10-12
Status
Completed
Phase
Early phase I
Treatment
sIPV batch 1
Type I 30 DU, Type II 32 DU, Type III 45 DU
Arms:
Batch 1 of sIPV
sIPV batch 2
Type I 30 DU, Type II 32 DU, Type III 45 DU
Arms:
Batch 2 of sIPV
sIPV batch 3
Type I 30 DU, Type II 32 DU, Type III 45 DU
Arms:
Batch 3 of sIPV
Size
1200
Primary endpoint
Seroconversion rate of neutralizing antibody
1 month after primary immunization
Local and systemic adverse reactions
Within 1 month after primary immunization
Eligibility criteria
Inclusion Criteria:
* Healthy infants of 2 months of age
* The legal identity certificate (birth/household register) and vaccination certificate of the participants can be provided, and the legal guardian can provide the legal identity certificate (identity card).
* Guardians are able to understand the experimental vaccine, volunteer to participate in the study and sign informed consent for participation.
* Guardians are capable of using thermometer, graduated scale, filling diary card and contact card.
* Participants are not vaccinated with polio vaccine and immunoglobulin (except for Hepatitis b specific immunoglobulin) after birth, no vaccination of live vaccine within 28 days before enrollment and no vaccination of inactivated vaccine within 14 days before enrollment.
* Participants or guardians are able to obey and follow all study instructions, complete all the monitoring, and cooperate to complete collection of blood sample.
* Axillary temperature ≤37℃
Exclusion Criteria:
* Allergic to any active substance, inactive substance or materials used during production such as kanamycin.
* Patients with fever or acute disease.
* Have thrombocytopenia or hemorrhagic diseases
* Patients undergoing immunosuppressive therapy or immunodeficiency
* Have uncontrolled epilepsy or other progressive neurological disorders
* Other situations that the investigator consider as non-eligible
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 1200, 'type': 'ACTUAL'}}
Updated at
2023-10-11
1 organization
1 product
1 indication
Product
sIPVIndication
Poliomyelitis